Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression

• Published in: The Journal of pathology Vol. 174; no. 1; p. 23
• Main Authors: Fontanini, G, Vignati, S, Bigini, D, Merlo, G R, Ribecchini, A, Angeletti, C A, Basolo, F, Pingitore, R, Bevilacqua, G
• Format: Journal Article
• Language: English
• Published: England 01-09-1994
• Subjects: Antigens, Neoplasm - analysis; Bronchi - pathology; Carcinoma in Situ - chemistry; Carcinoma, Non-Small-Cell Lung - chemistry; Carcinoma, Non-Small-Cell Lung - secondary; Disease Progression; Humans; Hyperplasia - metabolism; Immunoenzyme Techniques; Lung Neoplasms - chemistry; Metaplasia - metabolism; Neoplasm Invasiveness; Neoplasm Proteins - analysis; Precancerous Conditions - chemistry; Proliferating Cell Nuclear Antigen - analysis; Tumor Suppressor Protein p53 - analysis
• ISSN: 0022-3417
• DOI: 10.1002/path.1711740105

Mutations in the p53 tumour suppressor gene, with consequent accumulation of the p53 protein, are frequently observed in non-small cell lung cancer (NSCLC). Little is known, however, about the timing of their appearance or their maintenance through cancer progression and metastatic spread. We have examined the normal epithelium and a panel of bronchial lesions, including dysplastic, neoplastic, and metastatic lesions, for p53 immunoreactivity and for expression of proliferating cell nuclear antigen (PCNA). No p53 immunoreactivity was found in normal and hyperplastic epithelium, nor in squamous metaplastic lesions. Twenty out of 30 invasive tumours and 13 out of 17 in situ carcinomas adjacent to an invasive tumour showed p53 immunoreactivity. There was a strict correlation between the level of p53 expression in the non-invasive and the invasive components of the tumours. Five out of eight pairs of primary tumours and matching metastases expressed p53, at identical levels in both compartments. These data indicate that p53 overexpression can occur in the earliest recognized phase of NSCLC and that the alteration is maintained during progression from in situ to invasive carcinoma and metastatic spread. PCNA expression increased from early to advanced phases of NSCLC. High PCNA immunoreactivity was observed in tumours expressing high p53 levels. A significant association was observed for PCNA expression between preinvasive and invasive lesions.